Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Short Bowel Syndrome-Pipeline Insights, 2015 – A DelveInsight’s ReportDelveInsight, the leading market research and consulting company has added a new report “Short Bowel Syndrome-Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight.
By: DelveInsight Business Research · The report gives information of 8+ pipeline drugs with 7+ companies actively involved in drug development. There are 3 drugs which are in pre-clinical phase, 1 in phase I, 1 in phase I/II and 2 in clinical phase unknown. · NPS Pharmaceuticals, Inc. developed a lead product Gattex whichwas approved for Short Bowel Syndrome. · R& · Stages of development of pipeline molecules. · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, Short Bowel Syndrome-Pipeline Insights, 2015report provides the in-depth analysis of the pipeline assets across the Short Bowel Syndrome. Therefore the report on Short Bowel Syndrome-Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com Keywords DelveInsight, Indication Pipeline Insight report, collaborations, licensing Contact Us: DelveInsight Business Research New Delhi-110075, India Phone: +91-11-45689769, +91 9650213330 Website: http://delveinsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|